CVS Caremark recieves accreditation from URAC
WOONSOCKET, R.I. CVS Caremark announced on Wednesday that its pharmacy benefit management division, Caremark Pharmacy Services, has received accreditation from URAC, a Washington DC-based health care accrediting organization that establishes quality standards for the health care industry.
Caremark Pharmacy Services has received accreditation for two categories: Pharmacy Benefit Management and Drug Therapy Management. They are the first voluntary accreditations developed for the industry.
The process for both accreditations includes an application and evaluation process, an on-site evaluation and assessment by a URAC accreditation team, and review and consideration for accreditation by URAC’s Accreditation Committee.
“Our new URAC accreditations demonstrate Caremark’s continued commitment to not only meeting our industry’s standards, but also to exceeding them,” stated Howard McLure, president of Caremark Pharmacy Services. “We are pleased that our dedication to patient care, customer service and overall quality has been recognized by URAC, and we look forward to identifying new ways to further our standards of excellence as we move ahead.”
Mylan announces new appointments
PITTSBURGH Upon the news of the acquisition involving Merck’s KGaA generic business by Mylan, Mylan released a group of statements regarding new appointments to positions within the company worldwide.
The appointments include: Harry Korman as President, North America; Rajiv Malik as Executive Vice President in charge or Global Technical Operations; Carolyn Myers, Ph.D. President-elect of Dey; Christy Taylor as Chief Operating Officer of Dey; Didier Barret as President of Europe, Middle East, and Africa; Heather Bresch as Chief Operating Officer; and John Montgomery as President, Asia Pacific.
Mylan acquired Merck’s generics for $6.8 billion in cash.
FDA approves Afluria flu vaccine
AUSTRALIA The Food and Drug Administration has approved CSL’s flu vaccine Afluria, according to The Australian.
The company expects to ship two million doses as part of its first shipment to the U.S. between mid-December and early February. The company expects to increase its export to 20 million doses over the next four years.
“We’ve entered the US market quite late, but over the next few years we hope to increase our export of flu vaccine to the US to 20 million doses,” CSL’s Dr Rachel David said.